[go: up one dir, main page]

MX2022004451A - Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. - Google Patents

Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.

Info

Publication number
MX2022004451A
MX2022004451A MX2022004451A MX2022004451A MX2022004451A MX 2022004451 A MX2022004451 A MX 2022004451A MX 2022004451 A MX2022004451 A MX 2022004451A MX 2022004451 A MX2022004451 A MX 2022004451A MX 2022004451 A MX2022004451 A MX 2022004451A
Authority
MX
Mexico
Prior art keywords
sup
biphenyl
heteroaryl
amides
ligand
Prior art date
Application number
MX2022004451A
Other languages
English (en)
Inventor
Christopher W Lange
Rebecca M Lui
Yibin Zeng
Pingchen Fan
Penglie Zhang
Darren J Mcmurtrie
Ryan J Scamp
Ju Yang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2022004451A publication Critical patent/MX2022004451A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporcionan compuestos que son útiles como inmunomoduladores. Los compuestos tienen la Fórmula (I) (ver Fórmula) (I) incluidos estereoisómeros y sales farmacéuticamente aceptables de estos, donde R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 y n son como se definen en la presente. Adicionalmente se describen métodos relacionados con la preparación y el uso de estos compuestos, así como las composiciones farmacéuticas que comprenden estos compuestos.
MX2022004451A 2019-10-16 2020-10-15 Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. MX2022004451A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962915779P 2019-10-16 2019-10-16
US202063042796P 2020-06-23 2020-06-23
US202063057460P 2020-07-28 2020-07-28
PCT/US2020/055672 WO2021076691A1 (en) 2019-10-16 2020-10-15 Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases

Publications (1)

Publication Number Publication Date
MX2022004451A true MX2022004451A (es) 2022-05-03

Family

ID=75538873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004451A MX2022004451A (es) 2019-10-16 2020-10-15 Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.

Country Status (18)

Country Link
US (2) US11713307B2 (es)
EP (1) EP4045036A4 (es)
JP (1) JP7736678B2 (es)
KR (1) KR20220084119A (es)
CN (1) CN114585359B (es)
AU (1) AU2020368393B2 (es)
BR (1) BR112022006018A2 (es)
CA (1) CA3152329A1 (es)
CL (1) CL2022000956A1 (es)
CO (1) CO2022004723A2 (es)
CR (1) CR20220215A (es)
EC (1) ECSP22038478A (es)
IL (1) IL291642A (es)
MX (1) MX2022004451A (es)
PE (1) PE20221445A1 (es)
PH (1) PH12022550876A1 (es)
TW (1) TWI902711B (es)
WO (1) WO2021076691A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3755311B1 (en) 2018-02-22 2026-01-28 ChemoCentryx, Inc. Indane-amines as pd-l1 antagonists
CA3139526A1 (en) * 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
CA3152714A1 (en) 2019-10-16 2021-04-22 Pingchen Fan Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
PH12022550876A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
TW202216694A (zh) * 2020-06-23 2022-05-01 美商卡默森屈有限公司 使用雜芳基-聯苯醯胺衍生物治療癌症之方法
BR112023026747A2 (pt) 2021-06-18 2024-03-12 Aligos Therapeutics Inc Métodos e composições para direcionamento de pd-l1
US12428427B2 (en) 2021-12-16 2025-09-30 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
CN115010658B (zh) * 2022-05-11 2023-06-27 南方医科大学 一种化合物及其制备方法与应用
EP4626879A1 (en) * 2023-01-20 2025-10-08 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
WO2025015063A1 (en) * 2023-07-13 2025-01-16 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
WO2025174835A1 (en) * 2024-02-15 2025-08-21 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
ATE363470T1 (de) 2002-11-18 2007-06-15 Chemocentryx Inc Arylsulfonamide
EP1748989A2 (en) 2004-05-12 2007-02-07 ChemoCentryx Inc Aryl sulfonamides
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
DK1838674T3 (da) 2005-01-14 2011-06-14 Chemocentryx Inc Heteroarylsulfonamider og CCR2
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US7576218B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. 4-phenylpiperdine-pyrazole CCR1 antagonists
CA2629461C (en) 2005-11-10 2016-01-12 Anita Melikian Substituted quinolones and methods of use
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
AU2007245059B2 (en) 2006-03-31 2011-07-28 Novartis Ag New compounds
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
JP5266219B2 (ja) 2006-07-14 2013-08-21 ケモセントリックス， インコーポレイテッド トリアゾリルフェニルベンゼンスルホンアミド類
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
DE602007012261D1 (de) 2006-07-14 2011-03-10 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
DK2155712T3 (en) 2007-05-22 2016-12-19 Chemocentryx Inc 3- (imidazolyl) pyrazolo [3,4-b] pyridines
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
ATE548039T1 (de) 2007-07-12 2012-03-15 Chemocentryx Inc Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
WO2010024783A1 (en) * 2008-08-27 2010-03-04 Agency For Science, Technology And Research Biarylrhodanine and pyridylrhodanine compounds and their use
ES2536884T3 (es) 2008-09-11 2015-05-29 Chemocentryx, Inc. 4-Amino-3-(imidazolil)pirazol[3,4-d]pirimidinas
WO2010051561A1 (en) 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
CN102271681B (zh) 2008-11-04 2014-11-12 凯莫森特里克斯股份有限公司 Cxcr7调节剂
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
ES2528948T3 (es) 2009-09-21 2015-02-13 Chemocentryx, Inc. Derivados de pirrolidinona carboxamida como moduladores de quemerina-R (ChemR23)
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
BR112012033075B1 (pt) 2010-06-24 2021-06-01 Chemocentryx, Inc Composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto
UA114900C2 (uk) 2011-11-14 2017-08-28 Ігніта, Інк. Похідні урацилу як інгібітори axl і c-met-кінази
PL2785692T3 (pl) 2011-12-01 2018-02-28 Chemocentryx, Inc. Podstawione aniliny jako antagoniści ccr(4)
PT2785710T (pt) 2011-12-01 2017-12-18 Chemocentryx Inc Benzimidazóis e benzopirazóis substituídos como antagonistas de ccr(4)
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
WO2013130811A1 (en) * 2012-02-29 2013-09-06 Chemocentryx, Inc. Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
CA2892042C (en) 2012-11-29 2022-06-14 Chemocentryx, Inc. Cxcr7 antagonists
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
JP6306607B2 (ja) 2012-12-21 2018-04-04 ケモセントリックス，インコーポレイティド ジアゾールアミド
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2923184A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
PL3363790T3 (pl) 2013-09-06 2020-07-27 Aurigene Discovery Technologies Limited Pochodne 1,2,4-oksadiazolu jako immunomodulatory
SG11201601679TA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
MX2016007128A (es) 2013-12-02 2016-08-11 Chemocentryx Inc Compuestos del receptor 6 de quimiocina (ccr6).
GB201322334D0 (en) 2013-12-17 2014-01-29 Agency Science Tech & Res Maleimide derivatives as modulators of WNT pathway
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JP6767096B2 (ja) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
US10093658B2 (en) 2015-01-22 2018-10-09 Acquist Llc Bifunctional compounds and use for reducing uric acid levels
EP3294728A1 (en) 2015-05-13 2018-03-21 Selvita S.A. Substituted quinoxaline derivatives
MA42133A (fr) 2015-05-21 2021-06-02 Chemocentryx Inc Modulateurs du ccr2
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
NL1041468B1 (en) 2015-09-08 2017-03-22 Bosch Gmbh Robert Metal ring component of a drive belt for a continuously variable transmisson.
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
SMT202200369T1 (it) 2015-11-19 2022-11-18 Incyte Corp Composti eterociclici come immunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SG10202005790VA (en) 2015-12-22 2020-07-29 Incyte Corp Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
CN108698991B (zh) 2016-01-20 2022-08-23 凯莫森特里克斯股份有限公司 2-氧代吲哚化合物
CN108883122A (zh) * 2016-03-11 2018-11-23 菲姆布里昂医疗公司 有用于治疗疾病的c-糖苷化合物
MX384752B (es) * 2016-04-04 2025-03-14 Chemocentryx Inc ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
CR20200045A (es) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
JP6905053B2 (ja) 2016-05-23 2021-07-21 中国医学科学院薬物研究所Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ ベンジルフェニルエーテル誘導体、その調製方法、並びにその医薬組成物及び使用
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
CA3029256A1 (en) * 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
JP7168551B2 (ja) 2016-07-08 2022-11-09 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
KR102599339B1 (ko) 2016-12-20 2023-11-08 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 화합물
PL3558990T3 (pl) 2016-12-22 2022-12-19 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
WO2018119236A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
CN106674136B (zh) 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
EP3564237A4 (en) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
KR20190133714A (ko) 2017-03-27 2019-12-03 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 치환된 이소퀴놀린 유도체
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
JP7141130B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
KR102574135B1 (ko) 2017-07-10 2023-09-01 메디바이오파마 에스.엘. 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체
MA49701A (fr) 2017-07-28 2020-06-03 Chemocentryx Inc Composés immunomodulateurs
JP7198269B2 (ja) 2017-08-08 2022-12-28 ケモセントリックス，インコーポレイティド 大員環免疫調節剤
WO2019034172A1 (zh) 2017-08-18 2019-02-21 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
BR112020005284A2 (pt) 2017-09-25 2020-09-24 Chemocentryx, Inc. terapia de combinação usando um antagonista do receptor de quimiocina 2 (ccr2) e um inibidor de pd-1/pd-l1
US20190275015A1 (en) 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
WO2019070643A1 (en) 2017-10-03 2019-04-11 Bristol-Myers Squibb Company IMMUNOMODULATORS
WO2019074241A1 (ko) 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
WO2019120297A1 (zh) 2017-12-22 2019-06-27 上海海雁医药科技有限公司 免疫调节剂及其制法与医药上的用途
EP3733659B1 (en) 2017-12-29 2023-12-20 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
CN111868061A (zh) 2018-01-23 2020-10-30 百时美施贵宝公司 用作免疫调节剂的2,8-二酰基-2,8-二氮杂螺[5.5]十一烷化合物
KR102534185B1 (ko) 2018-02-05 2023-05-18 아비스코 테라퓨틱스 컴퍼니 리미티드 비아릴 유도체, 이의 합성법과 그 약학적 용법
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
EP3755311B1 (en) 2018-02-22 2026-01-28 ChemoCentryx, Inc. Indane-amines as pd-l1 antagonists
US11578054B2 (en) 2018-03-01 2023-02-14 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
WO2019174533A1 (zh) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
WO2019191624A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
UA128453C2 (uk) 2018-03-30 2024-07-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
CN111936475B (zh) 2018-04-03 2024-05-10 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
WO2020011209A1 (zh) 2018-07-11 2020-01-16 上海和誉生物医药科技有限公司 免疫抑制剂及其制备方法和在药学上的应用
WO2020011243A1 (en) 2018-07-12 2020-01-16 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
WO2020015716A1 (en) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
US20210300909A1 (en) 2018-07-19 2021-09-30 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
US20210347785A1 (en) 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
US20210236476A1 (en) 2018-08-29 2021-08-05 Chemocentryx, Inc. Methods of treating cancer with small molecule pd-l1 inhibitors
EA202091694A1 (ru) 2018-10-17 2021-02-10 Джилид Сайэнс, Инк. Ингибиторы pd-1/pd-l1
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
US20200297708A1 (en) 2019-03-19 2020-09-24 Chemocentryx, Inc. Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
CA3139526A1 (en) * 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
KR102841588B1 (ko) 2019-06-20 2025-08-01 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
CA3152690A1 (en) * 2019-09-30 2021-04-08 Lingyun Wu Compound as small molecule inhibitor pd-1/pd-l1 and application thereof
CA3152714A1 (en) 2019-10-16 2021-04-22 Pingchen Fan Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
KR20220102669A (ko) 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제
PH12022550876A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
TW202216694A (zh) 2020-06-23 2022-05-01 美商卡默森屈有限公司 使用雜芳基-聯苯醯胺衍生物治療癌症之方法

Also Published As

Publication number Publication date
CA3152329A1 (en) 2021-04-22
PE20221445A1 (es) 2022-09-21
TW202128651A (zh) 2021-08-01
BR112022006018A2 (pt) 2022-07-12
US11713307B2 (en) 2023-08-01
US20230322731A1 (en) 2023-10-12
EP4045036A4 (en) 2023-11-15
US20210130325A1 (en) 2021-05-06
JP2022551973A (ja) 2022-12-14
CN114585359A (zh) 2022-06-03
AU2020368393B2 (en) 2026-01-08
KR20220084119A (ko) 2022-06-21
WO2021076691A1 (en) 2021-04-22
TWI902711B (zh) 2025-11-01
PH12022550876A1 (en) 2023-03-27
CO2022004723A2 (es) 2022-04-29
IL291642A (en) 2022-05-01
CN114585359B (zh) 2025-08-12
CR20220215A (es) 2022-09-14
EP4045036A1 (en) 2022-08-24
US12497383B2 (en) 2025-12-16
CL2022000956A1 (es) 2023-01-13
ECSP22038478A (es) 2022-06-30
AU2020368393A1 (en) 2022-04-21
JP7736678B2 (ja) 2025-09-09

Similar Documents

Publication Publication Date Title
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CL2024000067A1 (es) Compuestos antivirales
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
ZA202206923B (en) New methylquinazolinone derivatives
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
EP4609866A3 (en) Oxysterols and methods of use thereof
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
PH12021552482A1 (en) Compounds targeting prmt5
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
PH12022551523A1 (en) Cyclic compounds and methods of using same
MY199779A (en) Pyrrolopyrimidine compound and use thereof
PH12021552513A1 (en) Pyrrole compounds
MX2021007247A (es) Derivados de rapamicina.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
PH12021552953A1 (en) Tricyclic compounds
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof